Alterity Therapeutics has been granted a new U.S. composition of matter patent for ATH434. New composition of matter patent secures key intellectual property for ATH434 and may strengthen long-term development and market positioning.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | 1 | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Cash | 10.62 | 8.29 | 21.47 | 25.33 |
| Receivables | 5.83 | 2.65 | 2.55 | 5.23 |
| Inventory | — | — | — | — |
| Other | 1.76 | 1.55 | 5.68 | 0.55 |
| 18.21 | 12.48 | 29.71 | 31.10 |
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Payables | 2.37 | 3.03 | 1.67 | 1.38 |
| ST’ Debt | 0.07 | — | — | — |
| Other | 0.49 | 0.41 | 0.57 | 0.70 |
| 2.95 | 3.52 | 2.29 | 2.14 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’21 | — | — | — | — |
3.37
|
| ’20 | — | — | — | — |
0.09
|
| ’19 | — | — | — | — |
3.62
|
| ’18 | — | — | — | — |
2.58
|
| ’17 | — | — | — | — |
2.38
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’26 | — | (15.29) | — | (6.97) |
(15.29)
|
| ’25 | — | (7.42) | — | (5.44) |
(7.42)
|
| ’24 | — | (8.27) | — | (2.93) |
(8.27)
|
| ’23 | — | (13.49) | — | (6.53) |
(13.49)
|
| ’22 | — | (8.95) | — | (6.32) |
(8.95)
|
| ’21 | — | (12.95) | — | 5.36 |
(12.95)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’26 | — | (15.29) | — | (6.97) |
(15.29)
|
| ’25 | — | (7.42) | — | (5.44) |
(7.42)
|
| ’24 | — | (8.27) | — | (2.93) |
(8.27)
|
| ’23 | — | (13.49) | — | (6.53) |
(13.49)
|
| ’22 | — | (9.02) | — | (6.32) |
(9.02)
|
| ’21 | — | (12.96) | — | 5.36 |
(12.96)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’26 | — | — | — | — |
(0.91)
|
| ’25 | — | — | — | — |
(0.74)
|
| ’23 | — | 0.00 | — | 0.00 |
(0.01)
|
| ’22 | — | 0.00 | — | 0.00 |
(0.01)
|
| ’21 | — | 0.00 | — | (0.01) |
(0.01)
|
| ’20 | — | (0.01) | — | (0.01) |
(0.01)
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 2.90 | 1.55 | 1.00 | 2.52 | 3.02 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 12.30 | 5.41 | 3.88 | 7.00 | 5.89 | — | — | — |
High Price
|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 12 | 12 | 10 | 9 | 9 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.27) | (9.22) | (12.51) | (7.82) | (15.81) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.32) | (9.29) | (12.54) | (7.87) | (15.91) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.04 | 0.07 | 0.10 | 0.09 | 0.08 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.45) | (2.31) | (2.02) | (0.74) | (0.91) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.23) | (3.33) | (1.36) | (0.70) | (0.87) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.25) | (3.33) | (1.36) | (0.70) | (0.87) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.42 | 3.80 | 1.49 | 2.58 | 1.65 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.01 | 4.05 | 6.08 | 10.66 | 17.54 | — | — | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | — | — | — | — |
PE Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | — | — | — | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — |
PB Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | — | — | — | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.95) | (13.49) | (8.27) | (7.42) | (15.29) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.06) | 0.00 | 0.00 | — | — | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.02) | (13.49) | (8.27) | (7.42) | (15.29) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.63 | 15.26 | 8.96 | 27.42 | 28.96 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.08 | 0.14 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (25.17) | (10.48) | (8.29) | (21.47) | (25.33) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.73 | 15.36 | 9.05 | 27.46 | 29.00 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.83%) | (38.41%) | (80.92%) | (37.10%) | (52.04%) | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (1,416.98%) | (149.65%) | (1,248.22%) | (135.49%) | (327.72%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (38.44%) | (45.24%) | (102.77%) | (43.10%) | (56.26%) | — | — | — |
ROE
|
Alterity Therapeutics Limited (ATHE), a clinical-stage biotech targeting Parkinson’s and multiple system atrophy, embodies the high-stakes volatility of speculative drug development. Stemming from Prana Biotechnology’s rebrand after a 2014 Phase 2 flop that cratered its stock, ATHE now grapples with zero revenue since 2021, widening losses, and relentless cash burn averaging $8.5 million annually—funded entirely by dilutive equity raises that ballooned shares outstanding over 1,100% in recent years. Analyst consensus signals a stark 99% downside, underscoring the precarious balance sheet propped up by net cash but vulnerable to trial failures and funding squeezes.
While a modest net cash cushion offers 2-3 years’ runway and projections hint at narrowing losses (EPS improving to -0.74 in 2025) alongside working capital growth, efficiency metrics like abysmal ROE (-0.55 average) and ROA reveal poor capital allocation in a pre-revenue firm. Absent insider buying and with historical price plunges mirroring revenue droughts, ATHE demands caution for conservative portfolios chasing steady performers.
Key catalysts loom in 2025-2026 ATH434 Phase 2 data, potentially validating its alpha-synuclein mechanism amid Big Pharma stumbles—but biotech’s 90%+ Phase 2 failure rate amplifies wipeout risks. Dilution, macro headwinds, and unproven milestones skew the reward heavily negative; the full analysis details why risk-averse investors should avoid or monitor with tight stops.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.